Graphite Bio, Inc. Profile Avatar - Palmy Investing

Graphite Bio, Inc.

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly co…

Biotechnology
US, South San Francisco [HQ]
Strategy & Leadership

Officers & BofD Beta

  • Form 3/4/5
  • Proxy DEF-14A

Total Compensation

- No data, only available if we have DEF 14A compensations in place -
Officers
Name & Position Research Last Appearance
- No data available -
Board of Directors (BofD)
Name & Position Research Last Appearance
- No data available -
End of GRPH's Analysis
CIK: 1815776 CUSIP: 38870X104 ISIN: US38870X1046 LEI: - UEI: -
Secondary Listings
GRPH has no secondary listings inside our databases.